For instance, in advanced prostate cancer, EZH2 participates in gene repression in an enzyme-activity-dependent manner, but also acts as a transcriptional activator to occupy promoters of androgen receptor genes (Kim et al., 2018; Xu et al., 2012). This evidence concerns the gene EZH2 and prostate carcinoma.